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The phorbol ester, 12-O-tetradecanoylphorbol 13-ace-
tate (TPA), a potent stimulator of Erk, leads to the phos-
phorylation of 4E-BP1 and its dissociation from eIF4E.
In contrast to agonists such as insulin, this occurs inde-
pendently of PKB activation. In this report, we investi-
gate the mechanism by which TPA regulates 4E-BP1
phosphorylation. Treatment of HEK293 cells with TPA
was found to result in the phosphorylation of 4E-BP1 at
Ser64, Thr69, and Thr36/45. The TPA-stimulated phospho-
rylation of all these sites is sensitive to inhibitors of
MEK and to the inhibitor of mTOR, rapamycin, indicat-
ing that inputs from both mTOR and MEK are required
for the regulation of 4E-BP1 phosphorylation by TPA.
Indeed, evidence is presented that mTOR may initially
be required for the phosphorylation of Thr45 in a prim-
ing step, which is necessary for the subsequent phospho-
rylation of Ser64 and Thr69 through an Erk-dependent
pathway. Overexpression of constitutively active MEK
in HEK293 cells resulted both in the phosphorylation of
4E-BP1 at Ser64 and Thr36/45 and its release from eIF4E.
In this case, the phosphorylation of these sites was also
blocked by inhibitors of MEK or by rapamycin. In con-
clusion, the Erk pathway, via mechanisms also requir-
ing mTOR, regulates the phosphorylation of multiple
sites in 4E-BP1 in vivo and this is sufficient for the
release of 4E-BP1 from eIF4E.
mRNA translation is conventionally divided into three stag-
es: initiation, elongation, and termination. Of these, initiation
is considered the rate-limiting step and therefore is considered
the most important step in the acute regulation of translation.
Essential for initiation of cap-dependent protein synthesis is
the assembly of the initiation complex, eukaryotic initiation
factor (eIF)1 4F, containing the initiation factors eIF4G, a large
scaffolding protein, eIF4E, the protein which binds to the 5 cap
structure and eIF4A, a bidirectional RNA helicase (for review,
see Ref. 1). The formation of the eIF4F complex is regulated by
a variety of stimuli through the activation of multiple signal
transduction pathways. eIF4E-binding protein-1 (4E-BP1),
also known as protein-heat and acid-stable I, is a translational
repressor that regulates eIF4F assembly and therefore cap-de-
pendent translation (for review, see Ref. 1). 4E-BP1 binds to a
site on eIF4E that overlaps the binding site for eIF4G and it
therefore competes with eIF4G for binding to eIF4E, which
results in the inhibition of eIF4F assembly (2–4). The binding
of 4E-BP1 to eIF4E is regulated through the phosphorylation of
4E-BP1. Phosphorylation of 4E-BP1 leads to a reduction in its
affinity for eIF4E and its subsequent dissociation from eIF4E
(2, 5–8).
Five phosphorylation sites each conforming to a (S/T)P motif
have been identified in 4E-BP1; Thr36, Thr45, Ser64, Thr69, and
Ser82 (based on rat sequence, 1 for human (9–11)). The phos-
phorylation of 4E-BP1 at Thr45 and Ser64, sites adjacent to the
conserved eIF4E-binding motif, is thought to be the most im-
portant in influencing the binding of 4E-BP1 to eIF4E (12, 13).
However, each site differentially influences the binding of 4E-
BP1 to eIF4E and mRNA translation by affecting either the
affinity of 4E-BP1 for eIF4E or (indirectly) influencing the
phosphorylation of other sites (12, 14).
The signaling pathways leading to insulin-induced increases
in the phosphorylation of 4E-BP1 have been the focus of much
attention. Insulin is thought to regulate the phosphorylation of
4E-BP1 through the phosphatidylinositol 3-kinase (PI 3-ki-
nase) signaling pathway (15) and this is thought to be depend-
ent on both the phosphorylation and activation of PKB (16, 17).
In vitro, 4E-BP1 is an excellent substrate for Erk, which phos-
phorylates all five sites, albeit with differing efficiencies (9).
Ser64 is the major in vitro Erk phosphorylation site and is also
a major site of phosphorylation in response to insulin in vivo (6,
9). However, in vivo, the activation of Erk appears neither
necessary nor sufficient for the phosphorylation of 4E-BP1 in
response to insulin (15, 18, 19).
Rapamycin, a specific inhibitor of mTOR, blocks the effects of
insulin or phorbol ester on the phosphorylation of 4E-BP1 (7,
18, 19). In vitro, immunoprecipitated mTOR can phosphorylate
4E-BP1 at Thr36, Thr45, Thr69, Ser64, and Ser82, albeit with low
and differing efficiencies (12, 20, 21).
We have previously shown that, in HEK 293 cells, the phor-
bol ester TPA stimulates the phosphorylation of 4E-BP1 via
mechanisms that are independent of PI 3-kinase and PKB (19).
The phosphorylation and regulation of 4E-BP1 by TPA are
inhibited by the MEK inhibitors PD098059 and U0126 indicat-
ing that the Erk pathway plays a role in the regulation of
4E-BP1 by TPA (19). In contrast, the regulation of 4E-BP1 by
insulin in these cells is independent of MEK. In addition, there
is an increasing number of other reports, using a variety of
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physiological stimuli, indicating a role for Erk pathway in the
phosphorylation of 4E-BP1 (22, 23).
In this report we demonstrate that TPA, a potent activator of
Erk, leads to the phosphorylation of 4E-BP1 at Thr36/45, Ser64,
and Thr69, and that this leads to the dissociation of eIF4E from
4E-BP1. Phosphorylation at these sites is sensitive to inhibi-
tors of MEK and rapamycin, indicating that inputs from both
mTOR and MEK are required for TPA regulation of 4E-BP1
phosphorylation. Additionally, activation of the Erk pathway in
HEK293 cells through the overexpression of constitutively ac-
tive MEK resulted in the phosphorylation of 4E-BP1 at posi-
tions Thr36/45 and Ser64, and its release from eIF4E.
MATERIALS AND METHODS
Chemicals and Materials—Microcystin LR, bisindolylmaleimide
(BIM), rapamycin, and PD098059 were purchased from Calbiochem.
Materials for tissue culture were from Invitrogen. m7GTP-Sepharose
was from Amersham Biosciences, Inc. U0126 was obtained from Pro-
mega. All other chemicals (unless stated) were obtained from Sigma.
PD184352 was provided by the Division of Signal Transduction Ther-
apy, Dundee University.
Cell Culture and Treatment of Cells—HEK293 cells were maintained
in Dulbecco’s modified Eagle’s media (Invitrogen) supplemented with
10% fetal calf serum. Prior to treatment, cells were grown to 80%
confluence before being serum starved for 18 h. Details of treatments
are provided in the figure legends. After treatment, cells were washed
in phosphate-buffered saline and lysed in extraction buffer (0.1% Triton
X-100, 50 mM -glycerophosphate, pH 7.4, 1.5 mM EGTA, 1 mM benza-
midine-HCl, 0.5 mM sodium orthovanadate, 0.1 mM phenylmethylsul-
fonyl fluoride, 1 g/ml each of pepstatin A, antipain, and leupeptin).
The lysates were then centrifuged for 10 min at 16,000  g. The
supernatants were removed and used for further analysis.
SDS-PAGE and Immunoblotting—SDS-PAGE and Western blotting
were performed as described previously (24). Anti-human eIF4E anti-
serum was raised against a synthetic peptide corresponding to residues
5–23 of the protein. The anti-4E-BP1 antibody was a generous gift from
Adri Thomas (Utrecht). Anti-phospho 4E-BP1, PKB, and Erk antibodies
were supplied by New England Biolabs. Anti-Erk5 antibodies were
obtained from Upstate Biotech. Densitometry was performed using the
program Image Quant (Amersham Biosciences, Inc.).
m7GTP-Sepharose Chromatography—m7GTP-Sepharose CL-6B (Am-
ersham Biosciences, Inc.) was added to 0.2–0.5 mg of cell lysate. The
lysates were then mixed with the beads for 1 h at 4 °C. The m7GTP-
Sepharose was pelleted by centrifugation at 1000 g for 2 min. The beads
were then washed three times in extraction buffer. For SDS-PAGE, pro-
teins were removed from the m7GTP matrix by boiling in SDS loading
buffer and, after centrifugation, the supernatant was loaded on to the gel.
Plasmids—A PCR directed fragment-encoding rat 4E-BP1 was di-
gested with HindIII and BamHI and cloned into pcDNA3.1myc/3his
(Invitrogen) to generate pcDNA3–4E-BP1 expressing Myc and His-
tagged 4E-BP1. The codon for residue Thr45 of 4E-BP1 within
pcDNA3–4E-BP1 was mutated to encode alanine using the
QuikChangeTM mutagenesis kit (Stratagene) producing the vector
pcDNA3–4E-BP1T45A. pCA-MEK expressing a constitutively active
form of MEK1 (N3-S218E/S222D MEK1), and pErk2-MEK-La ex-
pressing a constitutively active form of Erk (25), were kindly provided
by Drs. Axel Knebel (University of Dundee) and Melanie Cobb (Univer-
sity of Texas, Southwestern Medical Center, Dallas), respectively.
Transient Transfections—Transient transfections were performed as
described by Alessi et al. (26).
RESULTS
The Phorbol Ester, TPA, Leads to the Phosphorylation of
4E-BP1 through the Erk Pathway—We have previously pro-
vided evidence that the phorbol ester, TPA elicits the phospho-
rylation of 4E-BP1 though a mechanism that is dependent
upon MEK but independent of PI 3-kinase and PKB (19). To
characterize further the role of the MEK/Erk pathway in the
phosphorylation of 4E-BP1, we first investigated which sites
within 4E-BP1 were phosphorylated in response to TPA using
previously described phospho-specific antibodies (12).
To examine the phosphorylation state of 4E-BP1, Myc/His-
tagged 4E-BP1 (4E-BP1myc/his) was expressed in HEK293
cells. The cells were then treated with TPA, insulin, and/or
specific kinase inhibitors. As previously observed, TPA treat-
ment led to the phosphorylation of Erk (Fig. 1a) and a decrease
in the mobility of 4E-BP1 (Fig. 1b, i) on SDS-PAGE, which is
indicative of its phosphorylation. TPA caused an increase in the
phosphorylation of 4E-BP1myc/his at Ser64 and Thr69 and a
small increase in the phosphorylation of Thr36/45 as assessed
using anti-phospho-Ser(P)64, Thr(P)69, and Thr(P)36/45 specific
antibodies (Fig. 1b, ii-iv). Similar increases in the phosphoryl-
ation of 4E-BP1myc/his were detected when cells were stimu-
lated with insulin (Fig. 1b). A basal level of phosphorylation of
4E-BP1 at both Thr69 and Thr36/45 was also detected in serum-
starved untreated cells (Fig. 1b, iii and iv).
Pretreatment of the cells with each of three structurally
distinct inhibitors of MEK (the upstream activator of Erk),
PD098059, U0126, and PD184352 (27–29), resulted in a dose-
dependent inhibition of TPA-stimulated Erk phosphorylation
as assessed using an anti-phospho-Erk antibody (Fig. 1a, i) (as
a loading control the same samples were probed with anti-Erk
2 antibody (Fig. 1a, ii)). All three MEK inhibitors caused an
inhibition of TPA-stimulated 4E-BP1 phosphorylation at
FIG. 1. TPA stimulates 4E-BP1
phosphorylation through the MAP
kinase pathway. HEK293 cells tra-
nsiently transfected with pCDNA3– 4E-
BP1 were serum starved for 18 h. Cells
were pretreated with the indicated
inhibitors (PD98*, PD098059; U, U0126;
PD18*, PD184352; r rapamycin; B, BIM)
for 45 min prior to the addition of 1 M
TPA or 100 nM insulin (ins) for 1 h (or left
untreated (Un)). a, samples of cell lysates
(20 g) were applied to a SDS-polyacryla-
mide gel followed by Western blotting
using: (i) anti-phospho Erk and (ii) anti-
Erk2 antisera. b, samples of cell lysates
(20 g) were run on a SDS-polyacryla-
mide gel followed by Western blotting
using: (i) anti-Myc antibody or (ii-iv)
phospho-specific antibodies against 4E-
BP1. The positions of the three forms of
4E-BP1 separated in this gel system (, ,
and,  in order of increasing state of
phosphorylation) are indicated. (ii) anti-
phospho Ser64; (iii) anti-phospho Thr69;
and (iv) anti-phospho Thr36/45 antisera.
Similar data were obtained from three
separate experiments.
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Ser64 and partially blocked the phosphorylation at Thr69 and
Thr36/45. These inhibitors also decreased the basal phosphoryl-
ation of 4E-BP1 at Thr69 and Thr36/45 (Fig. 1b, iii and iv).
It has been reported that each of the three MEK inhibitors
used in this study can also inhibit MEK5, the upstream acti-
vator of Erk5 (30, 31). Thus, it was possible that the effect of
these inhibitors was through inhibition of Erk5. We therefore
investigated whether TPA could cause phosphorylation of Erk5
in HEK293 cells. HEK293 cells were treated with TPA and
extracts were analyzed by SDS-PAGE and immunoblotting
using an anti-Erk5 antibody (Fig. 2). As a positive control,
HeLa cell lysates treated with EGF were run alongside (32).
EGF treatment of HeLa cells leads to the phosphorylation of
Erk5 as indicated by a shift in its mobility on SDS-PAGE.
However, no phosphorylation of Erk5 was detected upon TPA
stimulation of HEK293 cells (Fig. 2), thus excluding a role for
this pathway in the effect of TPA on 4E-BP1.
Pretreatment of HEK293 cells with rapamycin, inhibited the
TPA-stimulated phosphorylation of 4E-BP1 at Ser64 and abol-
ished or markedly inhibited both basal and its TPA-stimulated
phosphorylation at Thr69 and Thr36/45, respectively (Fig. 1b).
However, rapamycin had no effect on the phosphorylation of
Erk (Fig. 1a), suggesting that it exerts its effect independently
of the MEK/Erk pathway.
TPA activates both classical and novel PKC isoforms (33).
Consistent with this, pretreatment of cells with the broad spec-
trum PKC inhibitor BIM inhibited the effect of TPA on the
phosphorylation of both Erk and 4E-BP1myc/his (Fig. 1, a and
b).
These results provide strong evidence that the Erk pathway
(specifically MEK) plays a role in the phosphorylation of 4E-
BP1myc/his at Ser64, Thr69, and Thr36/45 induced by TPA.
TPA Stimulated Phosphorylation of 4E-BP1 at Thr36, Ser64,
and Thr69 Requires Phosphorylation at Thr45—It has previ-
ously been reported that the extent of insulin-stimulated phos-
phorylation of 4E-BP1 at one site can modulate the phospho-
rylation of another site, with Thr36 or Thr45 having the most
dramatic influence on the phosphorylation at other sites (12,
14, 34).
To investigate whether TPA-stimulated 4E-BP1 phosphoryl-
ation was regulated similarly, Thr45 of 4E-BP1 was mutated to
an alanine creating the vector 4E-BP1T45A Myc/His. The phos-
phorylation of overexpressed 4E-BP1T45A Myc/His and 4E-
BP1myc/his upon insulin or TPA stimulation was monitored
using the phospho-specific antibodies. As previously shown (see
Fig. 1), stimulation of cells with either TPA or insulin resulted
in the phosphorylation of 4E-BP1myc/his at Thr36/45, Ser64, and
Thr69 (Fig. 3). In contrast, neither TPA nor insulin led to the
phosphorylation of 4E-BP1T45A Myc/His at Thr36 or Ser64 and
there was a severe reduction in the phosphorylation at Thr69
(Fig. 3). This suggests that phosphorylation of these residues in
4E-BP1 in response to TPA depends upon (prior) phosphoryla-
tion of 4E-BP1 at Thr45, as suggested earlier for the phospho-
rylation of 4E-BP1 in response to insulin or serum (34, 35).
Transient Transfection of Constitutively Active MEK Leads to
the Phosphorylation of 4E-BP1—To demonstrate directly that
MEK plays a role in the phosphorylation of 4E-BP1, HEK293
cells were transiently co-transfected with the vector pCA-MEK
encoding constitutively active MEK (CA-MEK) together with
pcDNA3–4E-BP1 encoding 4E-BP1myc/his. As a control, cells
were co-transfected with pcDNA3–4E-BP1 and an empty vec-
tor. The phosphorylation of 4E-BP1myc/his was investigated
using phospho-specific antibodies for Thr36/45, Ser64, and Thr69.
Overexpression of CA-MEK led to the phosphorylation of Erk
and a decrease in the mobility of 4E-BP1myc/his on SDS-
PAGE, indicative of increased phosphorylation (Fig. 4, a and b,
i). Overexpression of CA-MEK resulted in the phosphorylation
of Ser64 (Fig. 4b, ii) and increased phosphorylation at Thr36/45
as assessed using phospho-specific antibodies (Fig. 4b, iii). In
contrast to the situation for cells treated with TPA, no signifi-
cant change in the phosphorylation of Thr69 was detected.
However, some variation between experiments in the basal/
control levels of phosphorylation at Thr36/45 and Thr69 was
observed. Treatment of cells overexpressing CA-MEK and 4E-
BP1myc/his with U0126, PD098059, or PD184352, inhibitors of
MEK (27, 28), resulted in inhibition of the phosphorylation of
4E-BP1myc/his at Thr36/45 and Ser64 in parallel with the inhi-
bition of Erk phosphorylation. In general, U0126 was more
effective than PD098059 at inhibiting the phosphorylation of
both Erk and 4E-BP1myc/his. This most likely reflects differ-
ences in the mechanisms by which these two inhibitors work.
U0126 is thought to block the activity of MEK whereas
PD098059 is thought to inhibit MEK activation (27, 28, 36).
Incubation of cells expressing CA-MEK with rapamycin, an
inhibitor of mTOR, also inhibited CA-MEK-induced phospho-
rylation of 4E-BP1 at Ser64 and abolished or markedly inhib-
ited both basal and MEK-stimulated phosphorylation at
Thr36/45 and Thr69, respectively, without affecting the phospho-
rylation of Erk (Fig. 4, a and b).
The activation of MEK may lead to the activation of various
PKC isoforms including PKC, which itself has been implicated
in the phosphorylation of 4E-BP1 (37). To investigate whether
MEK was acting through PKC, cells expressing CA-MEK were
treated with the PKC inhibitor BIM. In contrast to the effect of
BIM on TPA stimulated phosphorylation of 4E-BP1 (Fig. 1),
BIM had only a small effect on the phosphorylation of 4E-BP1
at the sites investigated (Fig. 4, a and b), indicating that PKC
was probably not mediating the effect of CA-MEK.
To rule out the possibility that MEK activation could lead to
the phosphorylation of 4E-BP1 through activation of PKB, the
phosphorylation status of PKB in cells expressing constitu-
tively active MEK was monitored using a phospho-specific an-
FIG. 2. TPA does not cause the phosphorylation of Erk5.
HEK293 or HeLa cells were serum starved for 18 h. Cells were treated
with either TPA or epidermal growth factor (EGF) as indicated. 20 g
of cell lysates were run on a SDS-polyacrylamide gel followed by West-
ern blotting using anti-Erk5 antiserum.
FIG. 3. TPA stimulated phosphorylation of 4E-BP1 at Thr36,
Ser64, and Thr69 requires phosphorylation at Thr45. HEK293 cells
transiently transfected with pcDNA3–4E-BP1 and pcDNA3–4E-BP1T-
45A were serum starved for 18 h. Cells were treated with either TPA or
insulin (Ins) for 1 h. 20 g of cell lysates were run on a SDS-polyac-
rylamide gel followed by Western blotting using: (i) anti-Myc, and (ii-iv)
phospho-specific antibodies for 4E-BP1. The positions of the three forms
of 4E-BP1 separated in this gel system are indicated (, , and  in
order of increasing state of phosphorylation). Similar data were obta-
ined from three separate experiments.
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tibody against Ser473. Phosphorylation of this site is required
for activation of PKB (26). As a positive control, cells were
treated with insulin. Insulin treatment resulted in a large
increase in the phosphorylation of PKB at Ser473. In contrast,
expression of constitutively active MEK did not (Fig. 4c). Thus,
CA-MEK does not activate PKB. These results provide evidence
that MEK activation leads to the phosphorylation of 4E-BP1myc/
his in vivo at Ser64 and Thr36/45 through an mTOR-dependent
mechanism, which does not involve activation of PKB.
Transient Transfection of Constitutively Active Erk Results in
the Phosphorylation of 4E-BP1—As an adjunct to the above and
to define the role of Erk (as opposed to MEK) in the phospho-
rylation of 4E-BP1, HEK293 cells were transiently co-trans-
fected with pcDNA3–4E-BP1 expressing 4E-BP1myc/his and
pERK2-MEK1-LA expressing a MEK/ERK fusion protein
which has constitutive Erk activity (25). As a control, cells were
co-transfected with pcDNA3–4E-BP1 and an empty vector. The
phosphorylation of 4E-BP1 was investigated using the phos-
pho-specific antibodies for Ser64 and Thr69. Expression of con-
stitutively active MEK/Erk led to the phosphorylation of 4E-
BP1myc/his at Ser64 and a shift in its mobility on SDS-PAGE
(Fig. 5). In contrast to cells stimulated with TPA, a small
increase in the phosphorylation of Ser69 was detected upon
expression of MEK-Erk. However, some variation in the basal/
control levels of Thr69 phosphorylation was observed between
experiments.
Pretreatment of the cells with PD098059, an inhibitor of
MEK (27, 28), resulted in the inhibition the phosphorylation of
Ser65 and a partial inhibition in the basal phosphorylation of
Ser69 in MEK-Erk expressing cells. This was in parallel with
the inhibition of Erk phosphorylation as assessed using a phos-
pho-specific antibody to Erk. As a loading control, identical
samples were probed with anti-Erk 2 antibody. Incubation of
these cells with rapamycin also inhibited Erk-stimulated and
basal phosphorylation of 4E-BP1myc/his at Ser64 and Thr69,
respectively. These results provide further, more direct, evi-
dence that Erk activation, rather than any possible conse-
quences of MEK activation, leads to the phosphorylation of
4E-BP1 in vivo.
Activation of the Erk Pathway Leads to the Release of 4E-BP1
from eIF4E—We have previously demonstrated that stimula-
tion of HEK293 cells with TPA leads to the phosphorylation of
FIG. 4. Constitutively active MEK regulates 4E-BP1 phospho-
rylation in vivo. HEK293 cells transiently transfected with pCA-MEK
and pcDNA3–4E-BP1 were serum starved for 18 h. Cells were treated
with the inhibitors indicated for 1 h (PD98, PD098059; U, U0126; PD18,
PD184352; r, rapamycin; B, BIM). a, 20 g of cell lysates were run on a
SDS-polyacrylamide gel followed by Western blotting using: (i) anti-
MEK, (ii) anti-phospho-Erk, or (iii) anti-Erk2 antisera. b, 20 g of cell
lysates were run on a SDS-polyacrylamide gel followed by Western
blotting using: (i) anti-Myc to detect 4E-BP1myc/his. The positions of
the three forms of 4E-BP1 separated in this gel system (, , and,  in
order of increasing state of phosphorylation) are indicated. (ii) anti-
phospho Ser64; (iii) anti-phospho Thr36/45; and (iv) anti-phospho-Thr69
antisera. c, 20 g of cell lysates were run on a SDS-polyacrylamide gel
followed by Western blotting using anti-phospho-PKB (Ser473). Similar
data were obtained from three separate experiments. The change in
phosphorylation is expressed as percentage of maximal phosphoryla-
tion are above blots b (ii-iv).
FIG. 5. Constitutively active Erk regulates 4E-BP1 phospho-
rylation in vivo. (a) HEK-293 cells transiently transfected with
pcDNA3–4E-BP1 or pcDNA3–4E-BP1 and pERK2-MEK1-LA were se-
rum starved for 18 h. Cells transfected with pcDNA3–4E-BP1 were
preincubated for 45 min with either 50 M PD098059 (PD) or 200 nM
rapamycin (R) prior to the treatment with 1 M TPA. Cells transiently
transfected with pcDNA3–4E-BP1 or pcDNA3–4E-BP1 and pERK2-
MEK1-LA were treated with 50 M PD098059 (PD) or 200 nM rapamy-
cin (R) for 1 h. 20 g of cell lysates were run on a SDS-polyacrylamide
gel followed by Western blotting using a, (i) anti-Myc to detect 4E-
BP1myc/his. The positions of the three forms of 4E-BP1 separated in
this gel system (, , and  in order of increasing state of phosphoryl-
ation) are indicated. (ii) Anti-phospho-Thr69. (iii) Anti-phospho Ser64. b,
(i) Anti-Erk. (ii) Anti-phospho Erk. These results are representative of
three separate experiments. The quantification of phosphorylation, ex-
pressed as percentage of maximal phosphorylation, is indicated above
blots a (ii and iii).
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4E-BP1 and its dissociation from eIF4E and that these effects
were blocked by inhibitors of MEK (19). To examine the role of
the Erk pathway in the binding of 4E-BP1 to eIF4E, serum-
starved HEK293 cells expressing 4E-BP1myc/his were treated
with TPA, insulin, or transfected with CA-MEK and the asso-
ciation of eIF4E with 4E-BP1 was studied using m7GTP-Sepha-
rose chromatography. TPA, insulin, or the overexpression of
CA-MEK led to the phosphorylation of 4E-BP1 (Fig. 6a) and to
the dissociation of both endogenous and 4E-BP1myc/his from
eIF4E (Fig. 6b). This indicates that the phosphorylation of
4E-BP1 through the activation of the Erk pathway is sufficient
for release of 4E-BP1 from eIF4E.
DISCUSSION
We have previously demonstrated that in HEK293 cells, TPA
causes the phosphorylation of 4E-BP1 and its dissociation from
eIF4E via a mechanism which is independent of PI 3-kinase
and PKB, but dependent on MEK (19). In this report we further
investigate the phosphorylation of 4E-BP1 by TPA by deter-
mining the sites at which 4E-BP1 is phosphorylated under
these conditions and identifying the signaling pathways which
lead to 4E-BP1 phosphorylation. Treatment of HEK293 cells
with TPA, a potent activator of Erk, results in the phosphoryl-
ation of 4E-BP1 at Thr69, Ser64, and Thr36/45 (Figs. 1, 3, and 6).
Phosphorylation at these sites is blocked by three structurally
distinct inhibitors of MEK, PD098059, U0126, and PD154352
(Fig. 1). Additionally, expression of constitutively active MEK
results in the phosphorylation of 4E-BP1 at Ser64 and Thr36/45
(Fig. 4). TPA and the expression of an activated form of MEK
each led to the dissociation of 4E-BP1 from eIF4E (Fig. 6).
Taken together, this provides strong evidence that the Erk
pathway regulates the phosphorylation and function of 4E-BP1
in vivo. In contrast to cells stimulated with TPA, expression of
an activated form of MEK did not lead to a significant increase
in the phosphorylation of 4E-BP1 at Thr69. However, TPA
stimulated phosphorylation of 4E-BP1 at Thr69 was sensitive to
inhibitors of MEK. One possible explanation for this apparent
discrepancy is that the phosphorylation of Thr69 requires both
the activation of Erk and an additional input provided by TPA,
which may activate multiple downstream pathways.
The phosphorylation of 4E-BP1 in response to TPA, consti-
tutively active MEK or Erk is blocked by rapamycin, a specific
inhibitor of mTOR (Figs. 1, 4, and 5). Interestingly, rapamycin
also inhibited the basal phosphorylation of 4E-BP1 at Thr36/45
(Figs. 1, 4, and 5). It has previously been demonstrated that
serum-stimulated phosphorylation of Thr36 or Thr45 is neces-
sary for the subsequent phosphorylation at Ser64 and Thr69 (34,
35). In this study we demonstrate that a Thr45 to Ala 4E-BP1
mutant does not undergo TPA-induced phosphorylation at
Ser64 or Thr69 (Fig. 3). This indicates that the phosphorylation
of Thr45 may be required for the subsequent phosphorylation of
Ser64 and Thr69. It is likely that mTOR, or an mTOR-depend-
ent kinase, phosphorylates 4E-BP1 at Thr36/45, as these sites
are sensitive to rapamycin in vivo. Additionally, mTOR has
been shown to phosphorylate these sites in vitro (12, 20). As
Thr45 is required for the phosphorylation of Ser64 and Thr69 it
would appear that phosphorylation by TPA may occur by a
similar two-step mechanism as it has been proposed for serum-
stimulated phosphorylation of 4E-BP1 (14, 34) (Fig. 7).
Erk is known to phosphorylate 4E-BP1 readily in vitro (6, 9,
18). However, Erk is unlikely to directly phosphorylate 4E-BP1
in vivo as Erk cannot phosphorylate 4E-BP1 bound to eIF4E
(18, 38). PKC has been reported to phosphorylate 4E-BP1 in
vivo (37). However, PKC or the conventional PKC isoforms
probably do not play a role in MEK-induced phosphorylation of
4E-BP1 at the sites investigated, as BIM had a small effect on
the MEK-induced phosphorylation of 4E-BP1 (Fig. 4). There-
fore, 4E-BP1 phosphorylation induced by TPA or activated
forms of MEK or Erk is likely to be through the activation of an
as yet unidentified kinase or kinases that are regulated
through MEK/Erk signaling.
The regulation of 4E-BP1 and eIF4F via MEK/Erk signaling
may be important for the control of translation by mitogenic
signals which do not activate PI 3-kinase/PKB. eIF4E is a
proto-oncogene (39–41) and MEK/Erk signaling involves two
upstream proto-oncogenes (ras and raf) so that the activation of
FIG. 6. Role of the Erk pathway in the release of 4E-BP1 from
eIF4E. HEK293 cells transiently transfected with pCA-MEK and
pcDNA3–4E-BP1 or pcDNA3–4E-BP1 were serum starved for 18 h.
Cells were either left untreated (), or treated with 100 nM insulin (Ins)
or 1 M TPA where indicated for 1 h. a, 20 g of cell lysates were run on
a SDS-polyacrylamide gel followed by Western blotting using (i) anti-
Myc to detect 4E-BP1myc/his. The positions of the three forms of 4E-
BP1 separated in this gel system (, , and  in order of increasing state
of phosphorylation) are indicated and (ii) anti-MEK antiserum. (iii)
Anti-phospho-Thr36/45. (iv) Anti-phospho-Thr69 antibodies or (v) anti-
phospho-Ser64. b, analysis of proteins isolated by m7GTP-Sepharose
pull down. Proteins were separated on a SDS-polyacrylamide gel fol-
lowed by Western blotting using antisera against either eIF4E or
4E-BP1.
FIG. 7. Diagram showing the possible mechanism and signal-
ing pathways leading to the phosphorylation of 4E-BP1. A two-
step mechanism may be required for TPA stimulated 4E-BP1 phospho-
rylation. First, mTOR activity is required for the phosphorylation of
Thr36/45, which acts as a priming step for the subsequent phosphoryla-
tion of Ser64 and Thr69 in response to insulin or TPA through the PI
3-kinase or Erk pathways, respectively.
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eIF4E, by release of the repressor 4E-BP1, may link the regu-
lation of translation to oncogenic signaling via MEK/Erk.
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